Anzeige
Erschienen in:
30.05.2018 | Leitthema
Therapeutic coma for the treatment of status epilepticus
Timing, choice of drug, and impact on prognosis
Erschienen in: Clinical Epileptology | Ausgabe 4/2018
Einloggen, um Zugang zu erhaltenAbstract
Background
There are scarce data available on the treatment of refractory status epilepticus (SE) where general anesthetics are recommended. However, these may be related to increased morbidity (and possibly mortality).
Question
When and how should therapeutic coma be used in this clinical setting?
Methods
Critical review of available international literature in the past 50 years as well as of personal experience.
Results
Patients with generalized convulsive or nonconvulsive SE in coma not responding to benzodiazepines and an antiepileptic drug should be treated under electroencephalographic (EEG) monitoring with coma induction and general anesthetics. Initially, midazolam/propofol seem to represent the safest options. A progressive weaning attempt should be made after 24 h without EEG seizures. Patients with absence SE should never be treated with coma, and in those with focal SE with preserved consciousness coma should be deferred after the trial of other nonsedating compounds. In cases of super-refractory SE, ketamine and/or a ketogenic diet may be considered.
Conclusion
In view of the limited current evidence, it seems reasonable to avoid indiscriminate use of general anesthetics in SE.